BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models.
Rauh U, Wei G, Serrano-Wu M, Kosmidis G, Kaulfuss S, Siegel F, Thede K, McFarland J, Lemke CT, Werbeck N, Nowak-Reppel K, Pilari S, Menz S, Ocker M, Zhang W, Davis K, Poncet-Montange G, Roth J, Daniels D, Kaushik VK, Hubbard B, Ziegelbauer K, Golub TR.
Rauh U, et al. Among authors: mcfarland j.
Nat Cancer. 2024 Aug 23. doi: 10.1038/s43018-024-00814-0. Online ahead of print.
Nat Cancer. 2024.
PMID: 39179926